The Platelet P2 Receptors in Thrombosis

Christian Gachet; Béatrice Hechler

doi:10.1055/s-2005-869521

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2005; 31(2): 162-167
DOI: 10.1055/s-2005-869521

The Platelet P2 Receptors in Thrombosis

Christian Gachet¹ ^, ² , Béatrice Hechler²

¹Researcher, Etablissement Français du Sang-Alsace, Strasbourg Cedex, France
²INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg Cedex, France

Abstract

ABSTRACT

Adenosine diphosphate (ADP) and adenosine triphosphate (ATP) play a crucial role in hemostasis and thrombosis, and their receptors are potential targets for antithrombotic drugs. The ATP-gated channel P2X₁ and the two G protein-coupled P2Y₁ and P2Y₁₂ ADP receptors selectively contribute to platelet aggregation. Because of its central role in the formation and stabilization of a thrombus, the P2Y₁₂ receptor is a well-established target of antithrombotic drugs such as clopidogrel, which has proven efficacy in many clinical trials and experimental models of thrombosis. Competitive P2Y₁₂ antagonists have also been shown to be effective in experimental thrombosis as well as in several clinical trials. Studies in P2Y₁ and P2X₁ knockout mice and experimental thrombosis models using selective P2Y₁ and P2X₁ antagonists have shown that, depending on the conditions, these receptors could also be potential targets for new antithrombotic drugs. Because both P2X₁ and P2Y₁ receptor inhibition result in milder prolongation of the bleeding time as compared with P2Y₁₂ inhibition, the idea is put forward that combinations of P2 receptor antagonists could improve efficacy with diminished hemorrhagic risk. However, further studies with stronger and more selective P2 receptor antagonists are required to validate such a point of view.

KEYWORDS

ADP - ATP - P2Y - P2X - antiplatelet drug - hemostasis

Full Text

References

REFERENCES

1 Hellem A. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest. 1960; 12(suppl) 1-117
2 Gaarder A, Jonsen J, Laland S et al.. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 1961; 192 531-532
3 Ollgard E. Macroscopic studies of platelet aggregation: nature of an aggregating factor in red blood cells and platelets. Thromb Diath Haemorrh. 1961; 6 86-97
4 Born G VR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962; 194 27-29
5 Born G V. Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view. Circulation. 1985; 72 741-746
6 Maffrand J P, Bernat A, Delebassee D et al.. ADP plays a key role in thrombogenesis in rats. Thromb Haemost. 1988; 59 225-230
7 Kinlough-Rathbone R L, Packham M A, Reimers H J et al.. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. J Lab Clin Med. 1977; 90 707-719
8 Reimers H. Adenine nucleotides in blood platelets. In: Longenecker G The Platelets: Physiology and Pharmacology. San Diego, CA; Academic Press 1985: 85-98
9 Cusack N J, Hourani S M. Platelet P2 receptors: from curiosity to clinical targets. J Auton Nerv Syst. 2000; 81 37-43
10 Humphries R G. Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials. Haematologica. 2000; 85 66-72
11 Herbert J M, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003; 3 113-122
12 Zawilska K M, Born G V, Begent N A. Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits. Br J Haematol. 1982; 50 317-325
13 Enjyoji K, Sevigny J, Lin Y et al.. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999; 5 1010-1017
14 Marcus A J, Broekman M J, Drosopoulos J H et al.. Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost. 2003; 1 2497-2509
15 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol. 1999; 19 2281-2285
16 Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost. 2005; 31 168-173
17 Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost. 2005; 31 150-161
18 Léon C, Freund M, Ravanat C et al.. Key role of the P2Y(1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation. 2001; 103 718-723
19 Léon C, Ravanat C, Freund M et al.. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol. 2003; 23 1941-1947
20 Léon C, Alex M, Klocke A et al.. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 2004; 103 594-600
21 Oury C, Toth-Zsamboki E, Thys C et al.. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost. 2001; 86 1264-1271
22 Oury C, Sticker E, Cornelissen H et al.. ATP augments vWF-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation. J Biol Chem. 2004; 279 26266-26273
23 Hechler B, Lenain N, Marchese P et al.. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med. 2003; 198 661-667
24 Cattaneo M, Marchese P, Jacobson K A, Ruggeri Z. New insights into the role of P2X1 in platelet function. Haematologica. 2002; 87 13-14
25 Hollopeter G JH, Vincent D, Li G et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409 202-207
26 Savi P, Pereillo J M, Uzabiaga M F et al.. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84 891-896
27 Cazenave J P, Gachet C. Pharmacology of ticlopidine and clopidogrel. In: Gresele P, Page C, Fuster V, Vermylen J Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge, UK; Cambridge University Press 2002: 929-939
28 Savi P, Herbert J-M. Clopridogrel and ticlopidine: P2Y12 ADP-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005; 31 174-183
29 Cattaneo M, Lecchi A, Randi A M et al.. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992; 80 2787-2796
30 Cattaneo M, Lecchi A, Lombardi R et al.. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet ‘primary secretion defect’ are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol. 2000; 20 E101-E106
31 Cattaneo M, Zighetti M L, Lombardi R et al.. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA. 2003; 100 1978-1983
32 Fontana P, Gaussem P, Aiach M et al.. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation. 2003; 108 2971-2973
33 Fontana P, Dupont A, Gandrille S et al.. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003; 108 989-995
34 Conley P B, Delaney S M. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol. 2003; 10 333-338
35 Dorsam R T, Kunapuli S P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004; 113 340-345
36 Dorsam R T, Murugappan S, Ding Z, Kunapuli S P. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003; 8 359-365
37 Bauer S M. ADP receptor antagonists as antiplatelet therapeutics. Expert Opin Emerg Drugs. 2003; 8 93-101
38 Shaver S R. P2Y receptors: biological advances and therapeutic opportunities. Curr Opin Drug Discov Devel. 2001; 4 665-670
39 Foster C J, Prosser D M, Agans J M et al.. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001; 107 1591-1598
40 Andre P, Delaney S M, LaRocca T et al.. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003; 112 398-406
41 Ingall A H, Dixon J, Bailey A et al.. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999; 42 213-220
42 Storey R F, Sanderson H M, White A E et al.. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000; 110 925-934
43 Freund M, Mantz F, Nicolini P et al.. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Thromb Haemost. 1993; 69 515-521
44 Yao S K, Ober J C, McNatt J et al.. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res. 1992; 70 39-48
45 Yao S K, McNatt J, Cui K et al.. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation. 1993; 88 2888-2893
46 Yao S K, Ober J C, Ferguson J J et al.. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol. 1994; 267 H488-H493
47 Herbert J M, Bernat A, Maffrand J P. Importance of platelets in experimental venous thrombosis in the rat. Blood. 1992; 80 2281-2286
48 Herbert J M, Bernat A, Sainte-Marie M et al.. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost. 1993; 69 268-271
49 Wang K, Zhou X, Zhou Z et al.. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol. 2003; 23 357-362
50 van Gestel M A, Heemskerk J W, Slaaf D W et al.. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol. 2003; 23 518-523
51 Huang J, Driscoll E M, Gonzales M L et al.. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther. 2000; 295 492-499
52 Boyer J L. Development of novel and reversible antagonists of P2Y12 receptors as antithrombotic drugs. Presented at the 2004 Purines Conference June 6-9, 2004 Chapel Hill, NC;
53 Patel R, Douglass J G, Cowlen M et al.. In vivo antiplatelet activity of a reversible P2Y12 receptor antagonist. Presented at the 2004 Purines Conference June 6-9, 2004 Chapel Hill, NC;
54 Andre P, LaRocca T, Delaney S M et al.. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation. 2003; 108 2697-2703
55 Cattaneo M, Canciani M T, Lecchi A et al.. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood. 1990; 75 1081-1086
56 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348 1329-1339
57 Steinhubl S R, Berger P B, Mann III J T et al.. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288 2411-2420
58 Mehta S R, Yusuf S, Peters R J et al.. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358 527-533
59 Yusuf S, Zhao F, Mehta S R et al.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345 494-502
60 Sugidachi A, Asai F, Ogawa T et al.. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000; 129 1439-1446
61 Sugidachi A, Asai F, Yoneda K et al.. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001; 132 47-54
62 Niitsu Y, Jakubowski J A, Sugidachi A, Asai F. Pharmacology of CS-747 (LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005; 31 184-194
63 Nurden A T, Nurden P. Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol. 2003; 23 158-159
64 Chattaraj S C. Cangrelor AstraZeneca. Curr Opin Investig Drugs. 2001; 2 250-255
65 Storey R F, Oldroyd K G, Wilcox R G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001; 85 401-407
66 Storey R F, Wilcox R G, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002; 13 407-413
67 Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther. 2002; 24 752-765
68 Fabre J E, Nguyen M, Latour A et al.. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999; 5 1199-1202
69 Léon C, Hechler B, Freund M et al.. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999; 104 1731-1737
70 Baurand A, Gachet C. The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev. 2003; 21 67-76
71 Baurand A, Raboisson P, Freund M et al.. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol. 2001; 412 213-221
72 Turner N A, Moake J L, McIntire L V. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 2001; 98 3340-3345
73 Goto S, Tamura N, Handa S. Effects of adenosine 5′-diphosphate (ADP) receptor blockade on platelet aggregation under flow. Blood. 2002; 99 4644-4646
74 Remijn J A, Wu Y P, Jeninga E H et al.. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol. 2002; 22 686-691
75 Lenain N, Freund M, Leon C et al.. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost. 2003; 1 1144-1149
76 Rosen E D, Raymond S, Zollman A et al.. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol. 2001; 158 1613-1622
77 Falati S, Gross P, Merrill-Skoloff G et al.. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002; 8 1175-1181
78 Lenain N, Freund M, Hechler B et al.. The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser induced model of arterial thrombosis in vivo. Presented at the ISTH meeting July 13-18, 2003 Birmingham, UK (abst);
79 Kim H S, Ohno M, Xu B et al.. 2-substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem. 2003; 46 4974-4987
80 Mahaut-Smith M P, Tolhurst G, Evans R J. Emerging roles for P2X1 receptors in platelet activation. Platelets. 2004; 15 131-144
81 Rolf M G, Brearley C A, Mahaut-Smith M P. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost. 2001; 85 303-308
82 Rolf M G, Mahaut-Smith M P. Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets. Thromb Haemost. 2002; 88 495-502
83 Oury C, Kuijpers M J, Toth-Zsamboki E et al.. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood. 2003; 101 3969-3976
84 Kassack M U, Braun K, Ganso M et al.. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004; 39 345-357
85 Zighetti M L, Ulmann H, Lecchi A et al.. Studies of the specificity of the suramin analogue (NF449) as P2X1 receptor antagonist. Haematologica. 2004 (abst); 89 19
86 Hechler B, JP C, Gachet C. Effect of NF449, a novel selective P2X1 receptor antagonist, on platelet activation and thrombosis. Haematologica. 2004; 89 18

Dr.
Christian Gachet

INSERM U.311, Etablissement Francais du Sang-Alsace

10, Rue Spielmann, BP N° 36, 67065 Strasbourg Cedex, France

Email: christian.gachet@efs-alsace.fr